Trial · NCT01190436
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 12 | Baseline, Week 12 | The change in diastolic and systolic BP at Week 12 was calculated as diastolic and systolic BP at Week 12 minus diastolic and systolic BP at baseline, respectively. |
| Primary | Percentage of Participants With Controlled BP | Week 12 | Controlled BP was defined as BP less than 130/80 mmHg. |
| Primary | Percentage of Participants With Response to Study Drug | Week 12 | Response to study drug was defined as lowering of systolic BP by at least 10 mmHg from baseline. |
| Primary | Mean Change From Baseline in Heart Rate at Week 12 | Baseline, Week 12 | The change in heart rate at Week 12 was calculated as the heart rate at Week 12 minus heart rate at baseline. |
| Primary | Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12 | Week 12 | |
| Secondary | Percentage of Participants With Increased Glycosylated Hemoglobin (HbA1c) at Week 12 | Week 12 | HbA1c represents the percentage of glycosylated hemoglobin. Percentage of participants with increased HbA1c (greater than 0.5% from baseline) at Week 12 was reported. |
| Secondary | Mean Change From Baseline in HbA1c at Week 12 | Baseline, Week 12 | HbA1c represents the percentage of glycosylated hemoglobin. The change in HbA1c at Week 12 was calculated as HbA1c at Week 12 minus HbA1c at baseline. |
| Secondary | Percentage of Participants With Increased Fasting Blood Sugar (FBS) at Week 12 | Week 12 | Percentage of participants with increased FBS (greater than 16 milligram per deciliter \[mg/dL\] from baseline) at Week 12 was reported. |
| Secondary | Mean Change From Baseline in Fasting Blood Sugar (FBS) Level at Week 12 | Baseline, Week 12 | The change in FBS level at Week 12 was calculated as FBS level at Week 12 minus FBS level at baseline. |
| Secondary | Mean Change From Baseline in Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol and Triglyceride Level at Week 12 | Baseline, Week 12 | The change in total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at Week 12 was calculated as total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at Week 12 minus total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at baseline, respectively. |
| Secondary | Number of Participants With Adverse Events (AEs) | Baseline up to Week 12 | An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01190436/registered